Literature DB >> 6660853

Effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on proliferation of human fibroblasts, peripheral blood mononuclear cells, and granulocyte-monocyte progenitor cells in vitro.

A E Wittek, P S Cohen, A M Arvin, S D Smith, C M Koropchak, E De Clercq.   

Abstract

Inhibition of human fibroblasts, granulocyte-monocyte progenitor cells, and lymphocytes was observed at (E)-5-(2-bromovinyl)-2'-deoxyuridine concentrations ranging from 21 to 197 micrograms/ml. These concentrations were 10- to 100-fold above usual serum concentrations after oral administration. (E)-5-(2-Bromovinyl)-2'-deoxyuridine compares favorably with currently used antivirals in terms of in vitro myelotoxicity and immunotoxicity.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6660853      PMCID： PMC185945          DOI： 10.1128/AAC.24.5.803

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Human bone marrow colony growth in agar-gel.

Authors:  B L Pike; W A Robinson
Journal:  J Cell Physiol       Date:  1970-08       Impact factor: 6.384

2.  Human cell lines that elaborate colon-stimulating activity for the marrow cells of man and other species.

Authors:  J F Di Persio; J K Brennan; M A Lichtman; B L Speiser
Journal:  Blood       Date:  1978-03       Impact factor: 22.113

3.  Differential affinities of 5-(2-halogenovinyl)-2'-deoxyuridines for deoxythymidine kinases of various origins.

Authors:  Y C Cheng; G Dutschman; E De Clercq; A S Jones; S G Rahim; G Verhelst; R T Walker
Journal:  Mol Pharmacol       Date:  1981-07       Impact factor: 4.436

4.  Comparative in vitro imunotoxicology of acyclovir and other antiviral agents.

Authors:  R W Steele; D J Marmer; R E Keeney
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

5.  Lack of toxicity of acyclovir to granulocyte progenitor cells in vitro.

Authors:  R W McGuffin; F M Shiota; J D Meyers
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

6.  Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster.

Authors:  E de Clercq; H Degreef; J Wildiers; G de Jonge; A Drochmans; J Descamps; P de Somer
Journal:  Br Med J       Date:  1980-11-01

7.  (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent.

Authors:  E De Clercq; J Descamps; P De Somer; P J Barr; A S Jones; R T Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

8.  Sensitivity of human granulopoiesis in vitro to adriamycin before and after exposure in vivo.

Authors:  H P Lohrmann; W Schreml
Journal:  Cancer Res       Date:  1979-02       Impact factor: 12.701

9.  (E)-5-(2-bromovinyl)-2'-Deoxyuridine in the treatment of experimental herpes simplex keratitis.

Authors:  P C Maudgal; E De Clercq; J Descamps; L Missotten; P De Somer; R Busson; H Vanderhaeghe; G Verhelst; R T Walker; A S Jones
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

10.  Effect of acyclovir on the proliferation of human fibroblasts and peripheral blood mononuclear cells.

Authors:  M J Levin; P L Leary; R D Arbeit
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191
View more
  1 in total

1.  Oral BVDU treatment of varicella and zoster in children with cancer.

Authors:  Y Benoit; G Laureys; M J Delbeke; E De Clercq
Journal:  Eur J Pediatr       Date:  1985-01       Impact factor: 3.183
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.